Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 3
2004 8
2005 16
2006 18
2007 18
2008 22
2009 34
2010 41
2011 39
2012 38
2013 27
2014 25
2015 33
2016 25
2017 14
2018 8
2019 10
2020 9
2021 6
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Results by year

Filters applied: . Clear all
Page 1
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, Masud N, Fell G, Mo X, Yilmaz AS, Grant J, Zhang A, Bernstock JD, Torio E, Ito H, Liu J, Shono N, Nowicki MO, Triggs D, Halloran P, Piranlioglu R, Soni H, Stopa B, Bi WL, Peruzzi P, Chen E, Malinowski SW, Prabhu MC, Zeng Y, Carlisle A, Rodig SJ, Wen PY, Lee EQ, Nayak L, Chukwueke U, Gonzalez Castro LN, Dumont SD, Batchelor T, Kittelberger K, Tikhonova E, Miheecheva N, Tabakov D, Shin N, Gorbacheva A, Shumskiy A, Frenkel F, Aguilar-Cordova E, Aguilar LK, Krisky D, Wechuck J, Manzanera A, Matheny C, Tak PP, Barone F, Kovarsky D, Tirosh I, Suvà ML, Wucherpfennig KW, Ligon K, Reardon DA, Chiocca EA. Ling AL, et al. Among authors: tak pp. Nature. 2023 Nov;623(7985):157-166. doi: 10.1038/s41586-023-06623-2. Epub 2023 Oct 18. Nature. 2023. PMID: 37853118 Free PMC article. Clinical Trial.
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.
Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar-Cordova E, Aguilar LK, Guzik BW, Barone F, Tak PP, Schregel K, Hoetker MS, Lederer JA, Chiocca EA, Tabatabai G, Lawler SE. Koch MS, et al. Mol Ther Oncolytics. 2022 Jul 31;26:275-288. doi: 10.1016/j.omto.2022.07.009. eCollection 2022 Sep 15. Mol Ther Oncolytics. 2022. PMID: 36032633 Free PMC article.
Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics-Driven Machine Learning Approach.
Myasoedova E, Athreya AP, Crowson CS, Davis JM 3rd, Warrington KJ, Walchak RC, Carlson E, Kalari KR, Bongartz T, Tak PP, van Vollenhoven RF, Padyukov L, Emery P, Morgan A, Wang L, Weinshilboum RM, Matteson EL; Pharmacogenetics of Methotrexate in Rheumatoid Arthritis Consortium. Myasoedova E, et al. Among authors: tak pp. Arthritis Care Res (Hoboken). 2022 Jun;74(6):879-888. doi: 10.1002/acr.24834. Epub 2022 Apr 6. Arthritis Care Res (Hoboken). 2022. PMID: 34902228 Free article.
361 results